Graft Rejection Clinical Trial
Verified date | September 2009 |
Source | National Eye Institute (NEI) |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Federal Government |
Study type | Interventional |
To determine whether histocompatibility matching of corneal transplant donors and recipients can reduce the incidence of graft rejection in high-risk patients.
Status | Completed |
Enrollment | 0 |
Est. completion date | September 1989 |
Est. primary completion date | |
Accepts healthy volunteers | |
Gender | Both |
Age group | 10 Years and older |
Eligibility |
Males and females age 10 years or older with two to four quadrants of corneal stroma
vascularization or a history of allograft rejection in the eye considered for surgery were
eligible for both studies in the CCTS. Patients must have been willing to participate in 3 years of followup. No one was eligible for the CCTS who had a condition that would greatly increase the risk of nonrejection graft failure, such as xerophthalmia or severe exposure keratopathy. Also excluded were patients with systemic diseases or with medication usage that might alter their immune response. |
Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
National Eye Institute (NEI) |
Fink N, Stark WJ, Maguire MG, Stulting D, Meyer R, Foulks G, Smith RE, Rapoza P. Effectiveness of histocompatibility matching in high-risk corneal transplantation: a summary of results from the Collaborative Corneal Transplantation Studies. Cesk Oftalmol. 1994 Feb;50(1):3-12. — View Citation
Hahn AB, Foulks GN, Enger C, Fink N, Stark WJ, Hopkins KA, Sanfilippo F. The association of lymphocytotoxic antibodies with corneal allograft rejection in high risk patients. The Collaborative Corneal Transplantation Studies Research Group. Transplantation. 1995 Jan 15;59(1):21-7. — View Citation
Kamp MT, Fink NE, Enger C, Maguire MG, Stark WJ, Stulting RD. Patient-reported symptoms associated with graft reactions in high-risk patients in the collaborative corneal transplantation studies. Collaborative Corneal Transplantation Studies Research Group. Cornea. 1995 Jan;14(1):43-8. — View Citation
Klein PK; Stark WJ; Maguire MG; Stulting RD; Collaborative Corneal Transplantation Research Group; Donor-recipient crossmatching and typing to avoid corneal allograft rejection, in Cavanaugh HD (ed)., The Cornea: The World Congress on the Cornea III, New York, Raven Press, 1988:395-398
Maguire MG, Stark WJ, Gottsch JD, Stulting RD, Sugar A, Fink NE, Schwartz A. Risk factors for corneal graft failure and rejection in the collaborative corneal transplantation studies. Collaborative Corneal Transplantation Studies Research Group. Ophthalmology. 1994 Sep;101(9):1536-47. — View Citation
McDonnell PJ, Enger C, Stark WJ, Stulting RD. Corneal thickness changes after high-risk penetrating keratoplasty. Collaborative Corneal Transplantation Study Group. Arch Ophthalmol. 1993 Oct;111(10):1374-81. — View Citation
Stark WJ, Stulting RD, Meyer RF, Foulks GN, Smith RE, Chandler JW, Maguire MG, Bias WB. Sharing tissue typing information from the collaborative corneal transplantation studies. Arch Ophthalmol. 1989 May;107(5):633. — View Citation
Stark WJ, Stulting RD, Thoft R. HLA matching and corneal transplantation. N Engl J Med. 1987 Dec 3;317(23):1476-7. — View Citation
The collaborative corneal transplantation studies (CCTS). Effectiveness of histocompatibility matching in high-risk corneal transplantation. The Collaborative Corneal Transplantation Studies Research Group. Arch Ophthalmol. 1992 Oct;110(10):1392-403. — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00771875 -
Randomized Trial for Mixed Acute Rejection
|
Phase 2 | |
Completed |
NCT00369382 -
Study Of The Safety And Efficacy Of Conversion From A CNI To Sirolimus In Renally-Impaired Heart Transplant Recipients
|
Phase 4 | |
Completed |
NCT01009619 -
Azithromycin in Bronchiolitis Obliterans Syndrome
|
Phase 4 | |
Not yet recruiting |
NCT05072951 -
Urine Biomarker for Kidney Transplant Rejection
|
||
Completed |
NCT01211509 -
Montelukast in Bronchiolitis Obliterans Syndrome
|
Phase 4 | |
Recruiting |
NCT01066689 -
Impact of Treatment With Rituximab on the Progression of Humoral Acute Rejection After Renal Transplantation
|
Phase 3 | |
Completed |
NCT00251004 -
Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients
|
Phase 3 | |
Completed |
NCT00254709 -
Study Evaluating Two Different Sirolimus-based Immunosuppressive Regimens in Elderly Kidney Transplant Recipients
|
Phase 4 | |
Recruiting |
NCT04851145 -
Mass Spectrometry-based Proteomics in Microvascular Inflammation Diagnosis in Kidney Transplantation.
|
N/A | |
Completed |
NCT00001984 -
Effectiveness of the Investigational Drug Campath-1H in Preventing Rejection of Transplanted Kidneys
|
Phase 2 | |
Completed |
NCT04488094 -
Diagnostic Validity of [18F]FSPG PET for the Assessment of Acute Rejection After Heart or Liver Transplantation
|
Phase 2 | |
Not yet recruiting |
NCT03147157 -
The Effect of Human Leukocyte Antigen Macthing on Guiding Tacrolimus Regimen After Liver Transplantation
|
N/A | |
Completed |
NCT00761787 -
Cardiac Allograft Rejection Gene Expression Observational (CARGO) II STUDY
|
N/A | |
Completed |
NCT00266123 -
Study Comparing Two Sirolimus Regimens vs. Tacrolimus and Mycophenolate Mofetil Regimen in Kidney Transplant Recipients
|
Phase 4 | |
Completed |
NCT00035555 -
Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney
|
Phase 2 | |
Completed |
NCT00001858 -
Monitoring for Tolerance to Kidney or Combined Kidney-Pancreas Transplants
|
||
Completed |
NCT00895583 -
Study Evaluating A Planned Transition From Tacrolimus To Sirolimus In Kidney Transplant Recipients
|
Phase 4 | |
Completed |
NCT00089947 -
A Study to Evaluate the Effect of Thymoglobulin and Reduced Doses of Steroids to Prevent Renal Transplant Rejection
|
Phase 2 | |
Enrolling by invitation |
NCT05285878 -
Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation
|
Phase 2 | |
Active, not recruiting |
NCT00619528 -
HLA-Identical Sibling Renal Transplant Tolerance
|
N/A |